Seneca Biopharma Inc fka SNCA

[biocqr]

Time Frame for Catalysts

In October, the company will announce updated ALS clinical trial data for 18 patients, including the six newest ALS patients. If this news is as positive as the previous ALS data, we could see a sharp rise in share price.

In January 2013, the company will announce the Phase Ib depression trial results for its neurogenic drug. Positive results for safety could give investors up to a 30% share price increase. Positive results for efficacy could easily double the share price.

The third catalyst could be a partnership or buyout announcement late in 2012, or Q1 of 2013. Investors could easily realize a 50% to 100% share price appreciation from today's level if a buyout or partnership were announced.

http://seekingalpha.com/article/859871-why-neuralstem-could-provide-a-10x-return